Deep Dive: Vitamin K Shot Refusals Linked to Higher Infant Bleeding Risk — Background, What Changed, Viewpoints, and What to Watch

Parenting · 7 November 2026 · Deep dive

Two large studies published this week quantify what pediatricians have been seeing on the ground: more parents are declining the routine newborn vitamin K shot, and the rate of infant bleeding is rising in parallel.

Background

Babies are born with low vitamin K stores. The nutrient is essential for blood clotting. Without the single intramuscular dose given within hours of birth, infants—especially exclusively breastfed ones—are at substantially higher risk of vitamin K deficiency bleeding (VKDB). The most serious form can cause intracranial hemorrhage weeks later. The shot has been standard in the United States since 1961. CDC and AAP continue to recommend it for all newborns.

What changed

On 5–6 November 2026, two analyses using Epic Cosmos electronic health records were published.

The JAMA study (Scott, Burris, Dysart and colleagues at Children’s Hospital of Philadelphia and partners) examined more than 5.2 million infants born 2017–2025. Nonreceipt of intramuscular vitamin K rose from 3.1% in 2017 to 6.8% in 2025. Infants without the shot had a 47% higher risk of any bleeding event by six months (adjusted risk ratio 1.47), more than double the risk of intracranial bleeding (ARR 2.43), and higher risk of death with a concurrent bleeding diagnosis during the birth hospitalization. Number needed to harm: roughly 114 additional nonrecipients for one extra bleeding event.

A companion analysis in JAMA Pediatrics covering more than 11 million infants found similar trends: vitamin K deficiency and VKDB rates rose sharply (VKDB up approximately 347% over the period), with the large majority of diagnosed cases occurring in infants who had not received the dose.

Pediatricians report the change is visible in delivery rooms. One neonatologist described days when half the newborns left without the shot.

Competing viewpoints

Public-health and clinical standard: The shot is a decades-old, low-cost intervention with a clear safety record and a measurable reduction in a rare but potentially devastating outcome. Declining uptake is occurring alongside broader mistrust of newborn interventions and vaccines. Clear, consistent counseling from prenatal and birth-hospital teams remains the primary lever.

Parental-choice framing: Some parents prefer to avoid intramuscular injections at birth, seek “natural” alternatives, or express concerns about pain, ingredients, or necessity. Oral vitamin K regimens exist in some countries but require multiple doses and have lower adherence; they are not the U.S. standard. Parents retain the right to decline after informed discussion.

Communication gap: Editorialists note that rare risks are hard to convey. Presenting absolute numbers (one additional bleed per ~114 nonrecipients) and the intracranial-bleeding differential may help clinicians frame the conversation without overstatement.

What to watch next

For families expecting or with a newborn: ask your birth team whether the vitamin K dose was given (or declined) and document the discussion. This is context for parents, not medical advice. Discuss individual circumstances with your clinician.

Sources: JAMA (Scott et al., 5 November 2026), JAMA Pediatrics companion analysis, CHOP and VCU statements, CDC vitamin K guidance, contemporaneous reporting from Reuters, CIDRAP, and Contemporary Pediatrics.